Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment

References

• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi:10.1038/nrendo.2017.15129219149
   PubMed Web of Science ®Google Scholar
• Halaweish I, Alam HB. Changing demographics of the american population. Surg Clin North Am. 2015;95(1):1–10. doi:10.1016/j.suc.2014.09.00225459538
   PubMed Web of Science ®Google Scholar
• Lee KMC, Sum WMR. Prevalence of diabetic retinopathy in patients with recently diagnosed diabetes mellitus. Clin Exp Optom. 2011;94(4):371–375. doi:10.1111/j.1444-0938.2010.00574.x21323731
   PubMed Web of Science ®Google Scholar
• Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic retinopathy. Prim Care. 2015;42(3):451–464. doi:10.1016/j.pop.2015.05.00526319349
   PubMed Web of Science ®Google Scholar
• Cohen SR, Gardner TW. Diabetic retinopathy and diabetic macular edema. Dev Ophthalmol. 2015;55:137–146. doi:10.1159/00043897026501152
   PubMedGoogle Scholar
• Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–e1234. doi:10.1016/S2214-109X(17)30393-529032195
   PubMed Web of Science ®Google Scholar
• Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics. 2009;64(2):16–20.:.
   PubMed Web of Science ®Google Scholar
• Massin P, Kaloustian E. The elderly diabetic’s eyes. Diabetes Metab. 2007;33(SUPPL. 1):S4. doi:10.1016/S1262-3636(07)80052-817702094
   PubMed Web of Science ®Google Scholar
• Scanlon PH, Aldington SJ, Stratton IM. Epidemiological issues in diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20(4):293–300. doi:10.4103/0974-9233.12000724339678
   PubMedGoogle Scholar
• Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin North Am. 2004;88(4):1001–1036. doi:10.1016/j.mcna.2004.04.01215308388
   PubMed Web of Science ®Google Scholar
• Minutolo R, Gabbai FB, Provenzano M, et al. Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies. Nephrol Dial Transplant. 2018;33(11):1942–1949. doi:10.1093/ndt/gfy03229509925
   PubMed Web of Science ®Google Scholar
• Sasso FC, Chiodini P, Carbonara O, et al. High cardiovascular risk in patients with type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. Nephrol Dial Transplant. 2012;27(6):2269–2274. doi:10.1093/ndt/gfr64422090446
   PubMed Web of Science ®Google Scholar
• Minutolo R, Sasso FC, Chiodini P, et al. Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. J Hypertens. 2006;24(8):1655–1661. doi:10.1097/01.hjh.0000239303.93872.3116877970
   PubMed Web of Science ®Google Scholar
• Marcucci M, Franchi C, Nobili A, et al. Defining aging phenotypes and related outcomes: clues to recognize frailty in hospitalized older patients. J Gerontol a Biol Sci Med Sci. 2017;72(3):395–402. doi:10.1093/gerona/glw18828364542
   PubMed Web of Science ®Google Scholar
• Corrao S, Santalucia P, Argano C, et al. Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. Eur J Intern Med. 2014;25(7):617–623. doi:10.1016/j.ejim.2014.06.02725051903
   PubMed Web of Science ®Google Scholar
• Mohamed MEI, El-Shaarawy EAA, Youakim MF, Shuaib DMA, Ahmed MM. Aging changes in the retina of male albino rat: a Histological, Ultrastructural and Immunohistochemical Study. Folia Morphol. 2019;78(2):237–258. doi:10.5603/FM.a2018.0075
   PubMed Web of Science ®Google Scholar
• Toyoda F, Tanaka Y, Ota A, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats. J Diabetes Res. 2014;2014:1–7. doi:10.1155/2014/672590
   Web of Science ®Google Scholar
• Harris A, Harris M, Biller J, et al. Aging affects the retrobulbar circulation differently in women and men. Arch Ophthalmol. 2000;118(8):1076–1080. doi:10.1001/archopht.118.8.107610922201
   PubMedGoogle Scholar
• Harris A, Ciulla TA, Chung HS, Martin B. Regulation of retinal and optic nerve blood flow. Arch Ophthalmol. 1998;116(11):1491–1495. doi:10.1001/archopht.116.11.14919823351
   PubMedGoogle Scholar
• Nag TC, Wadhwa S. Ultrastructure of the human retina in aging and various pathological states. Micron. 2012;43(7):759–781. doi:10.1016/j.micron.2012.01.01122445096
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Harris A, Latkany P, et al. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand. 2002;80(5):468–477. doi:10.1034/j.1600-0420.2002.800503.x12390156
   PubMedGoogle Scholar
• Shoshani Y, Harris A, Shoja MM, et al. Impaired ocular blood flow regulation in patients with open-angle glaucoma and diabetes. Clin Exp Ophthalmol. 2012;40(7):697–705. doi:10.1111/j.1442-9071.2012.02778.x22394354
   PubMed Web of Science ®Google Scholar
• Ma W, Wong WT. Aging changes in retinal microglia and their relevance to age-related retinal disease. Adv Exp Med Biol. 2016;854:73–78. doi:10.1007/978-3-319-17121-0_1126427396
   PubMed Web of Science ®Google Scholar
• Wang Y, Grenell A, Zhong F, et al. Metabolic signature of the aging eye in mice. Neurobiol Aging. 2018;71:223–233. doi:10.1016/j.neurobiolaging.2018.07.02430172221
   PubMed Web of Science ®Google Scholar
• Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids. 2012;42(4):1205–1220. doi:10.1007/s00726-010-0778-x20963455
   PubMed Web of Science ®Google Scholar
• Jadeja RN, Thounaojam MC, Bartoli M, Martin PM. Implications of NAD+ metabolism in the aging retina and retinal degeneration. Oxid Med Cell Longev. 2020;2020:1–12. doi:10.1155/2020/2692794
   Web of Science ®Google Scholar
• Yumnamcha T, Guerra M, Singh LP, Ibrahim AS. Metabolic dysregulation and neurovascular dysfunction in diabetic retinopathy. Antioxidants. 2020;9(12):1–22. doi:10.3390/antiox9121244
   Web of Science ®Google Scholar
• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–2664. doi:10.2337/diacare.26.9.265312941734
   PubMed Web of Science ®Google Scholar
• Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:1–13. doi:10.1155/2013/343560
   Google Scholar
• Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res. 2007;2007:61038. doi:10.1155/2007/6103818224243
   PubMedGoogle Scholar
• Hallam KMC, Li Q, Ananthakrishnan R, et al. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell. 2010;9(5):776–784. doi:10.1111/j.1474-9726.2010.00606.x20670350
   PubMed Web of Science ®Google Scholar
• Xu J, Chen LJ, Yu J, et al. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy. Cell Physiol Biochem. 2018;48(2):705–717. doi:10.1159/00049189730025404
   PubMedGoogle Scholar
• Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(10):4867–4874. doi:10.1167/iovs.10-588120876889
   PubMed Web of Science ®Google Scholar
• Aiello LP. The potential role of PKC β in diabetic retinopathy and macular edema. Surv Ophthalmol. 2002;47:S263–S269. doi:10.1016/S0039-6257(02)00391-012507628
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625. doi:10.2337/diabetes.54.6.161515919781
   PubMed Web of Science ®Google Scholar
• Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6). doi:10.3390/ijms19061816
   Web of Science ®Google Scholar
• Rudraraju M, Narayanan SP, Somanath PR. Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy. Pharmacol Res. 2020;161:105115. doi:10.1016/j.phrs.2020.10511532750417
   PubMed Web of Science ®Google Scholar
• Hashemi H, Khabazkhoob M, Nabovati P, et al. The prevalence of age-related eye disease in an elderly population. Ophthalmic Epidemiol. 2017;24(4):222–228. doi:10.1080/09286586.2016.127033528658589
   PubMed Web of Science ®Google Scholar
• Rees G, Xie J, Fenwick EK, et al. Association between diabetes-related eye complications and symptoms of anxiety and depression. JAMA Ophthalmol. 2016;134(9):1007–1014. doi:10.1001/jamaophthalmol.2016.221327387297
   PubMed Web of Science ®Google Scholar
• Hugenschmidt CE, Lovato JF, Ambrosius WT, et al. The cross-sectional and longitudinal associations of diabetic retinopathy with cognitive function and brain MRI findings: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2014;37(12):3244–3252. doi:10.2337/dc14-050225193529
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/nejmoa160714127633186
   PubMed Web of Science ®Google Scholar
• Singh RP, Elman MJ, Singh SK, Fung AE, Stoilov I. Advances in the treatment of diabetic retinopathy. J Diabetes Complications. 2019;33(12):107417. doi:10.1016/j.jdiacomp.2019.10741731669065
   PubMed Web of Science ®Google Scholar
• Liu Y, Li J, Ma J, Tong N. The threshold of the severity of diabetic retinopathy below which intensive glycemic control is beneficial in diabetic patients: estimation using data from large randomized clinical trials. J Diabetes Res. 2020;2020. doi:10.1155/2020/8765139.
   Web of Science ®Google Scholar
• Sasso FC, Pafundi PC, Gelso A, et al. High HDL cholesterol: a risk factor for diabetic retinopathy? Findings from NO BLIND Study. Diabetes Res Clin Pract. 2019;150:236–244. doi:10.1016/j.diabres.2019.03.02830904748
   PubMed Web of Science ®Google Scholar
• Primer KR, Psaltis PJ, Tan JTM, Bursill CA. The role of high-density lipoproteins in endothelial cell metabolism and diabetes-impaired angiogenesis. Int J Mol Sci. 2020;21(10):3633. doi:10.3390/ijms21103633
   PubMed Web of Science ®Google Scholar
• Sasso FC, Pafundi PC, Gelso A, et al. Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: findings from No Blind Study. Nutr Metab Cardiovasc Dis. 2019;29(9):923–930. doi:10.1016/j.numecd.2019.05.06531377186
   PubMed Web of Science ®Google Scholar
• Chen HJ, Wang CG, Dou HL, Feng XF, Xu YM, Ma ZZ. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy. Ann Thorac Surg. 2020;9(1):82–89. doi:10.21037/apm.2020.01.10
   Web of Science ®Google Scholar
• Hainsworth DP, Bebu I, Aiello LP, et al. Risk factors for retinopathy in type 1 diabetes: the DCCT/EDIC Study. Diabetes Care. 2019;42(5):875–882. doi:10.2337/dc18-230830833368
   PubMed Web of Science ®Google Scholar
• Wang SY, Andrews CA, Herman WH, Gardner TW, Stein JD. Incidence and risk factors for developing diabetic retinopathy among youths with type 1 or type 2 diabetes throughout the United States. Ophthalmology. 2017;124:424–430. doi:10.1016/j.ophtha.2016.10.03127914837
   PubMed Web of Science ®Google Scholar
• Safi H, Safi S, Hafezi-Moghadam A, Ahmadieh H. Early detection of diabetic retinopathy. Surv Ophthalmol. 2018;63(5):601–608. doi:10.1016/j.survophthal.2018.04.00329679616
   PubMed Web of Science ®Google Scholar
• Ellis MP, Lent-Schochet D, Lo T, Yiu G. Emerging concepts in the treatment of diabetic retinopathy. Curr Diab Rep. 2019;19(11). doi:10.1007/s11892-019-1276-5
   Web of Science ®Google Scholar
• Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428–431. doi:10.4103/0301-4738.10054222944754
   PubMed Web of Science ®Google Scholar
• Galiero R, Pafundi PC, Nevola R, et al. The importance of telemedicine during COVID-19 pandemic: a focus on diabetic retinopathy. J Diabetes Res. 2020;2020:1–8. doi:10.1155/2020/9036847
   Web of Science ®Google Scholar
• Gunasekeran DV, Ting DSW, Tan GSW, Wong TY. Artificial intelligence for diabetic retinopathy screening, prediction and management. Curr Opin Ophthalmol. 2020;31(5):357–365. doi:10.1097/ICU.000000000000069332740069
   PubMed Web of Science ®Google Scholar
• Bolinger MT, Antonetti DA. Moving past anti-VEGF: novel therapies for treating diabetic retinopathy. Int J Mol Sci. 2016;17(9):1498. doi:10.3390/ijms17091498
   Web of Science ®Google Scholar
• Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context. 2018;7. doi:10.7573/dic.212532.
   Google Scholar
• You Z-P, Zhang Y-L, Shi K, et al. Suppression of diabetic retinopathy with GLUT1 siRNA. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-07942-x
   Web of Science ®Google Scholar
• Mishra M, Duraisamy AJ, Kowluru RA. Sirt1: a guardian of the development of diabetic retinopathy. Diabetes. 2018;67(4):745–754. doi:10.2337/db17-099629311218
   PubMed Web of Science ®Google Scholar
• Whitehead M, Wickremasinghe S, Osborne A, Van Wijngaarden P, Martin KR. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018;18(12):1257–1270. doi:10.1080/14712598.2018.154583630408422
   PubMed Web of Science ®Google Scholar
• Wang JH, Roberts GE, Liu GS. Updates on gene therapy for diabetic retinopathy. Curr Diab Rep. 2020;20(7). doi:10.1007/s11892-020-01308-w
   Web of Science ®Google Scholar
• Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci. 2018;132(12):1329–1339. doi:10.1042/CS20171298
   PubMed Web of Science ®Google Scholar
• Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–2117. doi:10.1007/s00125-018-4670-730132036
   PubMed Web of Science ®Google Scholar
• Sha W, Wen S, Chen L, Xu B, Lei T, Zhou L. The role of SGLT2 inhibitor on the treatment of diabetic retinopathy. J Diabetes Res. 2020;2020:1–6. doi:10.1155/2020/8867875
   Web of Science ®Google Scholar
• May M, Framke T, Junker B, Framme C, Pielen A, Schindler C. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology. Ther Adv Endocrinol Metab. 2019;10. doi:10.1177/2042018819891886.
   Web of Science ®Google Scholar
• Genentech’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness. Genentech; 2020. Available from: https://www.gene.com/media/press-releases/14891/2020-12-20/genentechs-faricimab-meets-primary-endpo. Accessed 55, 2021.
   Google Scholar
• Mayersohn M. Pharmacokinetics in the elderly. Environ Health Perspect. 1994;102:119–124. doi:10.1289/ehp.94102s11119
   Web of Science ®Google Scholar
• Turnheim K. Drug therapy in the elderly. Exp Gerontol. 2004;39:1731–1738. doi:10.1016/j.exger.2004.05.01115582289
   PubMed Web of Science ®Google Scholar
• McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(2):163–184. doi:10.1124/pr.56.2.415169926
   PubMed Web of Science ®Google Scholar
• Del Amo EM, Rimpelä AK, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134–185. doi:10.1016/j.preteyeres.2016.12.00128028001
   PubMed Web of Science ®Google Scholar
• Jackson SHD. Pharmacodynamics in the elderly. J Royal Soc Med. 1994;87:5–7.
   Web of Science ®Google Scholar
• Andres TM, McGrane T, McEvoy MD, Allen BFS. Geriatric pharmacology: an update. Anesthesiol Clin. 2019;37(3):475–492. doi:10.1016/j.anclin.2019.04.00731337479
   PubMedGoogle Scholar
• Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. doi:10.1046/j.1365-2125.2003.02007.x14678335
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76. doi:10.1080/0360253090272267919514965
   PubMed Web of Science ®Google Scholar
• Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302–307. doi:10.1053/j.ackd.2010.05.00220610357
   PubMed Web of Science ®Google Scholar
• Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015;32(6):725–737. doi:10.1111/dme.1265125440507
   PubMed Web of Science ®Google Scholar
• Capoccia K, Odegard PS, Letassy N. Medication adherence with diabetes medication: a systematic review of the literature. Diabetes Educ. 2016;42(1):34–71. doi:10.1177/014572171561903826637240
   PubMed Web of Science ®Google Scholar
• Garoma D, Merga H, Hiko D. Determinants of diabetic retinopathy in Southwest Ethiopia: a Facility-Based Case-Control Study. BMC Public Health. 2020;20(1). doi:10.1186/s12889-020-08652-2
   Web of Science ®Google Scholar
• Rodgers JE, Thudium EM, Beyhaghi H, et al. Predictors of medication adherence in the elderly: the role of mental health. Med Care Res Rev. 2018;75(6):746–761. doi:10.1177/107755871769699229148336
   PubMed Web of Science ®Google Scholar
• MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging. 2005;22(3):231–255. doi:10.2165/00002512-200522030-0000515813656
   PubMed Web of Science ®Google Scholar
• Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20(4):764–771. doi:10.1016/S0149-2918(98)80139-29737835
   PubMed Web of Science ®Google Scholar
• Mohan V, Khunti K, Chan SP, et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther. 2020;11(1):15–35. doi:10.1007/s13300-019-00733-9
   PubMed Web of Science ®Google Scholar
• Arlt S, Lindner R, Rösler A, Von Renteln-kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25(12):1033–1047. doi:10.2165/0002512-200825120-0000519021302
   PubMed Web of Science ®Google Scholar
• Eppley SE, Mansberger SL, Ramanathan S, Lowry EA. Characteristics associated with adherence to annual dilated eye examinations among us patients with diagnosed diabetes. Ophthalmology. 2019;126(11):1492–1499. doi:10.1016/j.ophtha.2019.05.03331281055
   PubMed Web of Science ®Google Scholar
• Hartnett ME, Key IJ, Loyacano NM, Horswell RL, DeSalvo KB. Perceived barriers to diabetic eye care: Qualitative Study of patients and physicians. Arch Ophthalmol. 2005;123(3):387–391. doi:10.1001/archopht.123.3.38715767483
   PubMedGoogle Scholar
• Angermann R, Rauchegger T, Nowosielski Y, et al. Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2119–2125. doi:10.1007/s00417-019-04414-y31286206
   PubMed Web of Science ®Google Scholar
• Obeid A, Su D, Patel SN, et al. Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti–vascular endothelial growth factor. Ophthalmology. 2019;126(3):407–413. doi:10.1016/j.ophtha.2018.07.02730077614
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105(2):216–221. doi:10.1136/bjophthalmol-2020-31593332265201
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179–1187. doi:10.1016/j.oret.2018.06.00431047187
   PubMedGoogle Scholar